Literature DB >> 18057886

Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report.

Volker Schulze1, Stefan Steiner, Marcus Hennersdorf, Bodo-Eckehard Strauer.   

Abstract

Inappropriate sinus tachycardia is a disease which is relatively rarely found and sometimes difficult to treat. Up to now it has been mostly treated with a beta-blocker or verapamil. If this did not work sinus node modulation was considered. Since the relatively new selective IF-stream blocker ivabradine has been approved for the therapy of chronic stable angina pectoris, a new therapeutic option is available. As ivabradine is well tolerated and only few side effects are known, it may become a new therapeutic step between medication and the invasive sinus node modulation. We report the case of a young female patient with inappropriate sinus tachycardia where a sustained therapeutic success was achieved with ivabradine medication as an alternative therapeutic trial after various ineffective medications. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057886     DOI: 10.1159/000111931

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  5 in total

Review 1.  Treatment of inappropriate sinus tachycardia with ivabradine.

Authors:  Martino Annamaria; Pier Paolo Lupo; Sara Foresti; Guido De Ambroggi; Ermenegildo de Ruvo; Luigi Sciarra; Riccardo Cappato; Leonardo Calo
Journal:  J Interv Card Electrophysiol       Date:  2015-10-14       Impact factor: 1.900

2.  Treatment of inappropriate sinus tachycardia with ivabradine.

Authors:  Peter Rakovec
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia: efficacy of ivabradine.

Authors:  Emanuele Romeo; Nicola Grimaldi; Berardo Sarubbi; Michele D'Alto; Giuseppe Santarpia; Giancarlo Scognamiglio; Maria Giovanna Russo; Raffaele Calabrò
Journal:  Pediatr Cardiol       Date:  2011-04-09       Impact factor: 1.655

Review 4.  Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.

Authors:  Gordon F Rushworth; Philippe Lambrakis; Stephen J Leslie
Journal:  Ther Adv Drug Saf       Date:  2011-02

Review 5.  The Contribution of HCN4 to normal sinus node function in humans and animal models.

Authors:  Eyal Nof; Charles Antzelevitch; Michael Glikson
Journal:  Pacing Clin Electrophysiol       Date:  2009-10-01       Impact factor: 1.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.